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Chapter 39 
The Enigma of Graft 
Acceptance 
The demonstration by Medawar (1,2) that rejection is an immunologic response is conceded by most 
early workers in the field to have been the seed of 
clinical transplantation (3). Medawar's conclusion 
about the nature of rejection was strengthened when 
it was shown that corticosteroids and total body irra-
diation (TBI), which already were known to weaken 
immunologic responses, modestly but significantly 
prolonged skin graft survival (4-6). 
However, the relatively minor delay of rejection of 
rodent skin grafts with corticosteroids and TBI did 
not immediately excite dreams of clinical application. 
Nor did the 1953 article by Billingham, Brent, and 
Medawar that described permanent skin graft accep-
tance in a special circumstance not involving immu-
nosuppression (7). The unique circumstance was the 
inoculation of fetal or perinatal mice with immuno-
competent spleen cells. Instead of being rejected, 
these cells survived and endowed the recipient with 
the ability in later life to accept all allogeneic tissues 
(in this instance skin) from the original donor strain. 
The impetus and rationale for these experiments 
came originally from the observation by Owen that 
the calf equivalents (called freemartin cattle) of hu-
man fraternal (dizygotic> twins were permanent he-
matopoietic chimeras if placental fusion and fetal 
cross circulation had existed in utero (Fig. 39.1) (8). 
Burnet and Fenner predicted that such chimerism 
and the ability to exchange other tissues could be in-
duced by the kind of experiment eventually per-
formed by Billingham, Brent, and Medawar (9). 
At first, there was interest bv clinicians in inocula-
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tion of babies in utero or perinatally with a parental 
or other donor's immunocompetent cells on the off 
chance that tissues or organs from the donor might 
be needed at some time after birth (10). However, it 
was soon learned by Billingham and Brent with fur-
ther experiments in mice that the penalty for the pro-
phylactic infusion of such donor cells could be lethal 
graft versus host disease (GVHD) (11). Many of the 
inoculated mice became progressively emaciated 
(runt disease) and exhibited skin erosion, hair loss, 
diarrhea, diffuse pneumonitis, and characteristic 
changes in their lymphoid organs (11,12). 
The GVHD lesions in the various host lymphoid 
and nonlymphoid organs were associated with the 
presence of donor immune cells. In essence, the tram;-
planted immunologic apparatus proved capable of 
rejecting the host. In 1959, the three conditions for the 
occurrence of GVHD were summarized by Bill-
ingham: first, the presence of mature immunologi-
cally competent cells in the graft; second, sufficient 
time for these cells to react before they are rejected 
by the host; and, third, important histocompatibility 
antigens in the recipient, which are lacking in the 
transplant (12). Billingham and Brent both have de-
scribed in their memoirs how the threat of GVHD 
posed by the tolerance-inducing immunocompetent 
donor cells was recognized late-undoubtedly 
dampening an initial rush of optimism about the fea-
sibility of transplantation (13,14). 
The definition of tolerance given by Billingham, 
Brent, and Medawar was that it " ... represents the 
specific and systematic failure of the mechanism of 
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Fig.39.1 Artist depiction (drawn in 1961) of Owens' 
observation in freemartin cattle (8) and the subsequent 
experiment described by Anderson D, Billingham RE, 
Lamplin GH, and Medawar PB in the title of their article 
"The use of skin grafting to distinguish between monozygotic 
and dizygotic twins in cattle" (Heredity 1951;5:379-397). 
(Reproduced by permission from Stanl TE, Butz GW Jr. 
Surgical physiology of the transplantation of tissues and 
organs. Surg Clin North Am 1962;42:55,) 
immunological response which is brought about by 
exposing embryos, or very young animals to anti-
genic stimuli, i.e. to stimuli which would have caused 
older animals to have become sensitive or immune. It 
is due to a primary central failure of the mechanism 
of the immunological reaction, and not to some inter-
cession, at a peripheral level." (15) Twenty years later, 
Medawar reflected that others had altered the mean-
ing of tolerance-on one hand by expanding beyond 
what he and his colleagues had said, or on the other 
by unnecessarily linking tolerance to a single mecha-
nism of clonal deletion (today called negative selec-
tion). These ambiguities of definition underscored the 
poor understanding of what graft acceptance meant, 
which by this time was being achieved with immuno-
suppression in patients and in various kinds of ani-
mal experiments. Medawar concluded in 1973: "The 
balance of evidence upholds the belief that tolerance 
is a state of essential nonreactivity-one in which ei-
ther a specific immune capability or the clone of cells 
that exercises it is simply not present." (16) 
The objective of producing specific and stable 
allogeneic (medawarian) nonresponsiveness became 
-._- ---J U )f transplantation when in 1955, Main 
and Prehn simulated in adult mice an environment 
which was likened to that in perinatal Billingham-
Brent-Medawar animals (17). The three steps were: 
first, to cripple the immune system with supralethal 
TBI, next to rescue it with allogeneic bone marrow 
(creating a chimera), and finally to engraft skin from 
the bone marrow donor. The experiments were 
successful. 
Main and Prehn believed (this was later verified) 
that they had produced a bone marrow chimera: 
Should the injected homologous marrow cells and 
their descendants survive permanently, i.e. 
throughout the remaining life span of the host, the 
resultant animal would be a "pseudohybrid;' ge-
netically constituted as the recipient but with its 
bone marrow partially derived from [donor] cells. 
The transplanted marrow would not be capable of 
immunologic response to further grafts containing 
[donor] antigens. Since there is no reason to as-
sume that the host would offer greater resistance 
to a bone-marrow graft than to a skin graft, the 
results of this experiment are consistent with the 
cellular repopulation theory of radiation protec-
tion. For obvious reasons, much further work will 
be required before one could possibly expect a 
general solution to the homograft problem (17). 
When the results of Main and Prehn were con-
firmed by Trentin, the prototype strategy for induc-
tion of tolerance in large animals and in humans 
appeared at first to be obvious (18). Bad news was 
close behind. Within the next few months it became 
clear that GVHD similar to that described by Bill-
ingham and Brent in the perinatal mouse model 
could be expected almost invariably after all bone 
marrow engraftments that "took" except those from 
donors with a perfect major histocompatibility com-
plex (MHO match. 
MEDAWARIAN VERSUS 
"NON-MEDAWARIAN" GRAFT ACCEPTANCE 
Although the bubble had burst, Mannick and col-
leagues at Cooperstown, New York, produced bone 
marrow chimerism in 1958 in an irradiated beagle 
dog, followed by successful kidney allotransplanta-
tion from the original marrow donor (19). The animal 
lived for 73 days before dying of pneumonitis and 
was the first "successful" marrow-kidney chimera in 
a large animal. However, efforts by Hume and associ-
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ates and by others to extend the Main-Prehn irradia-
tion plus bone marrow technology to mongrel dog 
donor-recipient combinations were totally unsuc-
cessful (20). When dog lymphocyte antigen (DLA) 
typing was perfected in the late 1960s, Rapaport 
working with many of the original Cooperstown in-
vestigators explained why (21). Piece by piece, they 
compiled evidence that the irradiation strategy 
would work in dogs only when completely MHC-
compatible marrow donors were used-usually litter 
mates. Apparently such matching had been achieved 
by accident in Mannick's dog. Under all other condi-
tions, lethal GVHD, rejection, or both were to be ex-
pected. 
Long before this, it had been demonstrated by 
Robert Good of Minneapolis and by E. Donnall 
Thomas (who moved in 1963 from Cooperstown to 
Seattle) that avoidance of lethal GVHD in human 
beings would require the same perfect tissue (HLA) 
matching as in the Cooperstown beagle dog colony if 
the knockout treatment approach were used of de-
stroying and replacing the recipient immune system 
(22-24). This appreciation caused an early break in 
ranks between those interested in bone marrow trans-
plantation for the treatment of hematologic disorders 
and those to whom the bone marrow was only the 
means to the transplantation of a needed solid organ 
of which the kidney was the sole candidate at the 
time. 
From this point onward, the therapeutic philoso-
phies of bone marrow and solid organ transplanta-
tion took separate pathways-one dependent and the 
other seemingly independent of classical tolerance in-
duction. Much of the rest of this chapter will illustrate 
the folly of this dichotomy. 
BONE MARROW TRANSPLANT AND 
"MEDAWARIAN TOLERANCE" 
The requirement described earlier of a perfectly 
matched human donor meant that clinical bone mar-
row transplantation would be confined almost exclu-
sively to siblings. Despite the consequent donor pool 
limitations, bone marrow transplantation for hemato-
logic diseases and an assortment of other indications 
matured into accepted clinical therapy after the first 
clinical successes by Robert Good in 1968 (22-24). 
With the addition of continuous posttransplant main-
tenance immunosuppression with cyclosporine, 
FK-506, steroids, and antilymphoid antibodies that 
do not kill the bone marrow stem cells, the rigid lim-
454 FUTURE PROSPECTS 
its of donor acceptability set by the need for MHC 
compatibility have slowly expanded, but only 
slightly. 
UNON-MEDAWARIAN SOLID ORGAN 
ACCEPTANCE" 
With Total Body Irradiation 
Solid organ transplant surgeons were quick to 
abandon efforts to produce specific allogeneic unre-
sponsiveness with bone marrow. In Boston, Murray 
and colleagues used the Main-Prehn principle of re-
cipient preparation in their first two attempts at hu-
man kidney allotransplantation in 1958, but 
eliminated the bone marrow component for the next 
10 recipients, using sublethal TBI alone (25,26). 
Eleven of the 12 irradiated recipients, including the 2 
given supra lethal irradiation and bone marrow, died 
after 0 to 28 days. The sole survivor, the recipient of 
a fraternal twin kidney in January 1959 after being 
treated only with preoperative sublethal irradiation, 
lived for more than 20 years and was the first ex-
ample of a successful transplantation beyond the 
identical twin (25-27). 
Five months later in Paris, Hamburger and associ-
ates added a second successful fraternal twin case 
(28). Although neither the American nor French fra-
ternal twin recipient was exposed iatrogenically to 
donor bone marrow, the possibility remained that 
their individual placentas had cross-circulated with 
those of their kidney donors, partially or even com-
pletely mimicking the conditions of in utero tolerance 
induction described in freemartin cattle by Owen (8). 
This clearly could not be the explanation for success 
in an extraordinary further kidney transplant experi-
ence in France during 1960 and 1961 using TBI with-
out bone marrow reconstitution. Hamburger and 
coworkers succeeded with kidney transplantation 
from a sibling and a cousin; after undergoing retrans-
plantation 18 years later the latter patient now is a 
member of the French parliament and the longest 
surviving kidney allograft recipient (32 years) from 
that heroic and primitive era (28-30). 
Also in Paris, Rene Kuss had long-term survival of 
three of six irradiated patients treated with kidney 
transplantation from June 1960 through 1961 (31,32l. 
This was an extraordinary achievement because two 
of Kuss's long-surviving patients were given non-
related kidneys (the first in June 1960) that functioned 
for 17 and 18 months. During the critical period of 
1959 through most of 1962, the cumulative French ex-
perience was the principal justification to continue 
clinical kidney transplantation trials (30,33). By show-
ing that bone marrow chimerism was not a necessary 
condition for prolongation of kidney grafts, the stage 
was set for the transition to drug therapy. 
Those examining this period historically have been 
inclined to consider irradiation-induced and drug-
induced graft acceptance as different phenomena 
(26,27,34). However, it seems certain that the Boston 
and Paris fraternal twin kidney recipients, as well as 
the five long-SUrviving nontwin French recipients, 
had achieved to variable degrees the same kind of 
graft acceptance that later was seen in tens of thou-
sands of drug-treated patients after all kinds of whole 
organ transplantation. 
That this could happen with irradiation (but not 
why) was shown years later in beagle dog experi-
ments reported to the American Surgical Association 
by Felix Rapaport with the title "Induction of unre-
sponsiveness to major transplantable antigens in 
adult mammals." The descriptive subtitle was a cap-
sule summary of the original Main-Prehn therapeutic 
concept: "A Recapitulation of Ontogeny by Irradia-
tion and Bone Marrow." In these experiments, the 
recipient's own (not allogeneiC> bone marrow was rein-
fused for immunologic reconstitution after suprale-
thaI irradiation (21). If a kidney or any of the other 
solid organs from a well-matched allogeneic donor 
were transplanted at the correct time after the autolo-
gous bone marrow infusion, the allogeneic organ was 
accepted by the reinfused and repopulating recipient 
marrow, which in its original native state would have 
rejected it. 
Curiously little attention was paid at the time or 
subsequently to Rapaport's important discovery. The 
conditions in Rapaport's autologous bone marrow ex-
periments were analogous to those in Murray's frater-
nal twin and the historic French recipients whose 
own in situ sublethally irradiated and recovering 
bone marrows had not been normally reactive to allo-
geneic grafts (26,29,31). The conditions also resem-
bled those that recently have allowed the production 
of mixed allogeneiC chimerism (see later). 
With Drug Therapy 
In view of the historic developments through 1960, 
it was not surprising that the search for immunosup-
pressive drugs was focused on myelotoxic agents that 
were viewed at first as "space makers" for the new 
marrow, and thus the pharmacologic equivalent of 
TBI. In fact, cyclophosphamide and busulphan still 
are used in this context to prepare patients for bone 
marrow transplantation. Goodwin and colleagues of 
Los Angeles achieved sublethal bone marrow ''burn 
out" with methotrexate and cyclosphamide in a liv-
ing-related kidney recipient in September 1960, who 
subsequently developed rejection that was treated 
with prednisone. This was the first example of pro-
tracted human kidney graft survival with drug treat-
ment alone (35). 
Kidney transplant surgeons were quick to learn 
that myelotoxicity should be avoided, not deliber-
ately imposed. The most important step in this evolu-
tion was the discovery by Schwartz and Dameschek 
that 6-mercaptopurine was immunosuppressive 
without bone marrow depression in nontransplant 
models (36) and the demonstration by them and 
Meeker and colleagues that this drug could mitigate 
skin graft rejection in rats (37,38). Subsequently, 
Caine and Zukoski and coworkers independently 
showed that 6-mercaptopurine could delay the rejec-
tion of canine kidneys (39,40). However, all that had 
been achieved so far was delay of the inevitable rejec-
tion. This soon would change. 
Occasional examples of long-term or seemingly 
permanent allograft acceptance were observed 
throughout 1962 and 1963-defined as long survival 
of transplanted mongrel dog kidneys after a 4- to 12-
month course of 6-mercaptopurine (or its imidazole 
derivative, azathioprine) was stopped (Fig. 39.2) (41-
44). Since then, each new major immunosuppressive 
agent (or drug cocktail regimen) including cyclo-
sporine and FK-506 has generated excited claims of 
the same phenomenon. However; the most potent 
agents for induction of this state have been the poly-
clonal antilymphoid sera (ALS) and globulin (ALG) 
purified from them (45,46). Although variable in its 
incidence, the graft acceptance seen with all these 
modalities was indistinguishable and thus was not a 
treatment-specific phenomenon. 
This new kind of ultimately drug-free graft accep-
tance in dogs was easier to produce than with TBI 
(which had been impossible in outbred animals), but 
the number of absolute examples was (and is) ex-
tremely small in contrast to what can be achieved to-
day in small rodents. In summarizing his research 
with CaIne, Alexandre, Sheil, and others using 
6-mercaptopurine and azathioprine, Murray de-
scribed a 20-day mortality of approximately 50% and 
a 3-month mortalitv of 900/" in their best series of 120 
mongrel dogs given daily treatment; eventually a 
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handful of survIvmg animals was the distillation 
from 1000 experiments (26,43). The results in our Col-
orado research laboratory were similar but with one 
striking difference (33,47). Adrenocortical steroids 
were shown to reverse rejection in 88% of our dogs, 
sometimes in spectacular fashion, before the steroids 
usually caused fatal peptic erosions of the gastroin-
testinal tract (47). 
The animals proudly displayed as chronic survi-
vors were those precious few who had run the gaunt-
let of continuous therapy to the point where the 
drugs were discontinued. After withdrawal of treat-
ment, more than two thirds of the small residual 
group of canine survivors rejected their kidneys. The 
survivors that emerged drug free from this ruthless 
biologic filter did not begin to approach 5% of the 
starting animals in any of the three laboratories (Bos-
ton, Richmond, and Denver) in which canine experi-
ments with 6-mercaptopurine or azathioprine were 
actually done. It was on this dismal record that the 
clinical kidney transplant trials of the early 1960s 
were based. In a display of optimism that would not 
be tolerated in today's clinical research climate, the 
rare exception was given more weight than the cus-
tomary failure. Thus, the poor results came as no sur-
prise when the drugs were first used for patients in 
the same way as had been tried in the dogs (26,48). 
REJECTION REVERSAL AND "TOLERANCE" 
Because of the pessimism that resulted from these 
initial trials, the outcome when azathioprine and 
prednisone were combined at the University of Colo-
rado exceeded everyone's expectations (49,50) and 
precipitated a revolution in transplantation. Success 
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Fig.39.2 The original caption for 
this figure was "Demonstration of 
a high degree of tolerance in a dog 
treated with azathioprine four 
months after homotransplantation 
and bilateral nephrectomy. Good 
renal function has continued for 
more than a year after stopping 
immunosuppressive therapy." This 
was a mongrel recipient in 1962 of 
an unrelated kidney whose eventual 
survival was almost a decade. 
(Reproduced by permission from 
Sta'll TE, Experience in renal 
transplantation. Philadelphia: WB 
Saunders, 1964:164-170.> 
hinged on two crucial observations. First, it was 
shown in human beings that acute rejection was not, 
as had been commonly assumed, one of nature's most 
powerful and persevering processes. It usually could 
be reversed with prednisone-confirming what had 
been seen and belatedly reported in dogs (47). Al-
though other components of "cocktail" immunosup-
pression have changed, the value of steroids for 
management of acute rejection has not diminished 
through the years. 
The second and more fundamental observation 
was that something changed during the first weeks 
and months after successful kidney transplantation in 
the relation of the recipient to the graft. The pattern 
of recovery, in which the amount of drug treatment 
often became progressively less was the strongest tes-
timony that such a host-graft change had occurred at 
an early time, allowing the lifetime rehabilitation ot 
some of the patients. Of the first 64 patients in the 
Colorado series compiled between 1962 and March 
1964, 16 survived for the next 25 years; 2 eventually 
stopped all immunosuppression without rejection for 
25 and 27 years, thus mimicking completely the phe-
nomenon occasionally seen in dogs (30,50). 
The reversibility of rejection and change in host-
graft relationship eventually were verified with all 
other transplanted organs, beginning with the liver 
(51-53). Although its transplantation is technically 
difficult, the liver has appeared to enjoy an immuno-
logic privilege in that it is more resistant than any 
other organ to antibody-mediated rejection, more ca-
pable in some species of prolonged survival without 
treatment (first noted in the pig and later rat and 
mouse), more apt to remain rejection free when treat-
ment is stopped, and seemingly more capable of 
shielding contemporaneously transplanted organs of 
the same donor from rejection (52-58). This last quality 
has been called tolerogenicity. In fact, each of the solid 
organs including the heart has similar qualities but its 
own peculiarities of timing, vigor, and reversibility of 
rejection although these characteristics may be diffi-
cult to quantitate except where they can be studied si-
multaneously in the same recipient as with heart-lung 
or multivisceral abdominal transplantation (59-64). 
Despite these differences between organs, the cen-
tral therapeutic dogma governing their transplanta-
tion has changed very little in the 28 years since it was 
delineated for the kidney-except that the available 
drugs or biologic adjuvant procedures have improved 
(Table 39.1) (26,45,49-51,65-76). The dogma calls for 
daily treatment with one or two baseline drugs with 
further immune modulation by the highly dose-
maneuverable adrenocorticosteroids to whatever 
level is required to maintain stable graft function. 
This means that every patient goes through a trial 
and potential error experience as drugs are weaned 
to maintenance levels. However, as early as 1964, it 
alreadv was realized that with different tissues and 
organs the laws governing the onset, treatability, and 
reversal of rejection would apply generically (51). 
CELL MIGRATION AND CHIMERISM 
The "graft acceptance" defined above has been an 
immunologic enigma (43,77,78). An ancient clue that 
cell migration is central to the process was the re-
duced allogenicity noted by Woodruff and Woodruff 
in thvroid tissue during a period of privileged sanc-
tuary in the anterior chamber of the guinea pig eye 
before subcutaneous transplantation (79,80). Such 
Table 39.1 
Central Therapeutic Dogma 
1. Baseline therapy with 
one or two drugs 
2. Secondary adjustments 
with steroids with or 
without anti lymphoid 
agents 
3. Case-to-case trial (and 
potential error) of 
weaning 
Baseline Agents 
1. Azathioprine 
2. Cyclophosphamide 
3. Cyclosporine 
4. FKS06 
"adaptation" in combination with clonal attrition was 
used in 1963 to explain two crucial observations of 
the reversibility of rejection, and the later change in 
the host-graft relationship that often made it possible 
to lighten maintenance immunosuppression (see pre-
vious section). After transplantation, previously neg-
ative tuberculin, histoplasmin, and other skin tests in 
these bellwether patients always became positive to 
antigens that had provoked positive reactions in their 
donors. The results were correctly interpreted as 
adoptive transfer of donor cellular immunity "by leu-
kocytes in the renal vasculature and hilar lymphoid 
tissue." (81) This dear statement of cell migration into 
recipient tissues was not easy to defend nearly 30 
years ago because the kidney was thought to be 
"lymphoid cell-poor." The flash of insight faded away 
until it was rediscovered three decades later. 
In the meanwhile, the reversal of rejection and an 
altered host-graft relationship were soon docu-
mented after transplantation of all of the other com-
monly engrafted organs-using a variety of drug 
treatment regimens. In 1969, karyotyping studies of 
long-surviving human liver allografts obtained from 
cadaveric donors of the opposite sex showed that 
while the hepatocytes and endothelium of major 
blood vessels retained their donor specificity, the en-
tire macrophage system including the Kupffer cells 
was replaced with recipient cells (82,83). It was not 
known where the departed donor cells had gone, but 
their continued presence somewhere in the body was 
evidenced by the acquisition and maintenance in the 
recipient blood of new donor-specific immunoglobu-
lin (Gm) types (83,84), anti-red blood cell alloanti-
bodies when donors with ABO nonidentity were 
used (85), and new soluble class I HLA antigens (86). 
Although secretion of the new HLA types was attrib-
uted by Davies and colleagues (86) to the trans-
planted hepatocytes, these molecules also are known 
to come from bone marrow-derived macrophages or 
dendritic cells (87-89) and thus undoubtedly had, in 
part, the same extrahepatic sources after completion 
ot cell migration as the additional Gm types and anti-
red cell antibodies. 
The chimeric structure of the transplanted liver 
was considered to be a unique feature of this organ 
until the demonstration of lymphoid and dendritic 
cell replacement (with recipient cells) under FK-506 
immunosuppression in transplanted rat and human 
intestine (64,90,91). The two-way trattic was the same 
whether the bowel was engratted alone or as a part of 
.1 multi visceral allogratt that also contained the liver, 
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stomach. and pancreas. In the rats. the replaced do-
nor lymphoid and dendritic cells homed through vas-
cular routes to widely distributed host lymphoid 
tissues. creating a state of mixed allogeneic chime-
rism-free of lethal or even detectable GVHD except 
in special strain combinations in which there is a 
poorly understood imbalance between the graft and 
recipient immune systems (92,93). 
Similarly, GVHD has been a relatively minor prob-
lem in human beings after cadaveric small bowel or 
multivisceral allotransplantation (94). This was not 
surprising because mixed allogeneic or xenogeneic 
chimerism already had been shown to be GVHD re-
sistant after bone marrow transplantation (95,96). A 
possible explanation for the GVHD resistance is 
the "exhaustive differentiation" described by Webb. 
Morris, and Sprent (97). Thus powerful immune re-
sponses of coexisting donor and recipient immune 
cells, each to the other. could first cause reciprocal 
clonal expansion followed by peripheral clonal dele-
tion (97). If this is true, the current clinical dogma for 
bone marrow transplantation of deliberately "unbal-
ancing" the donor-recipient equation by host cytore-
ductive procedures bears reassessment. It seems 
clear that to the extent this is done. the marrow donor 
must have a perfect HLA match. To the extent that it 
is not done, the need for HLA matching is dimin-
ished. 
Recent reports have suggested that some variant of 
mixed chimerism is an essential feature of all success-
ful transplantations. no matter what the organ 
(98-100>. In experimental studies. heart and liver allo-
grafts and xenografts in FK506-treated rat recipients 
were repopulated by recipient lymphoid and den-
dritic cells. The donor cell traffic leaving the allografts 
in the other direction homed to the host lymphoid 
organs including the medulla of the thymus. with 
distribution of dendritic cells to nonlymphoid tissues 
as well. The ubiquitous peripheralization of donor 
dendritic and other cells after heart and liver trans-
plantation was qualitatively similar (but far less ex-
tensive) to that described earlier after transplantation 
of the small bowel and was similar in principle to the 
donor cell distribution in irradiation-induced fully 
xenogeneic (rat to mouse) chimeras (92.93,98). 
Thus, cell migration is a striking generic phenome-
non with all kinds of transplants. The donor cells de-
parting the solid organ grafts and the recipient cells 
entering them include the passenger leukocytes that 
were suggested by Snell and proved by Steinmuller 
458 FUTURE PROSPECTS 
to be the principal cause of allograft immunogenicitv 
(101-103). Steinman and Cohn (104-107) delineated 
the most important of these cells as a distinct family 
of bone marrow-derived antigen presenting dendriti~ 
leukocytes that are distributed throughout the body 
including the interstitium of the kidney, heart. and 
other organs once thought to be nearly devoid of im-
munologically active cells (108.109). 
With the expectation of ameliorating rejection. nu-
merous techniques to deplete the intensely immuno-
genic dendritic cells have been described. particularly 
after Hart, Winearls, and Fabre and Batchelor and 
colleagues showed how their presence in rat renal al-
lografts elicited strong primary T-cell-dependent allo-
immunity (110-117). Observations by Larsen, Austyn. 
and Morris and by others showing rapid bloodstream 
movement of allograft dendritic cells to the spleen 
have emphasized the role of central as opposed to 
intra graft mechanisms of sensitization (118-121). Sin-
gle-donor dendritic cells at the center of large clustlDr~ 
of recipient T cells in the spleen as well as in rat liwr 
allografts graphically denoted an efficient amplifica-
tion system of T-cell activation in both locations (121). 
The primary or derivative objective in much of the 
foregoing research was reduction of graft antigenic-
ity, a potentially self-defeating strategy and a viola-
tion of a fundamental tenant of Billingham, Brent. 
and Medawar that " ... the stimulus that confers tol-
erance must be fully antigenic." (15) In untreated rats. 
Prop and coworkers of Holland have shown that till' 
lymphoid-poor heart is less vigorously rejected than 
the lung that contains rich bronchus-associakd 
lymphoid tissue (BALT) (61.62). However, this ordl'" 
of susceptibility to rejection was reversed with one llr 
two postoperative doses of cyclosporine that com-
monly induced permanent acceptance of the lung but 
never of the heart. The authors explained the paradox 
by the greater ease and volume of the lung's 
lymphoid and dendritic cell migration in much the 
same context as in the intestinal repopulation discov-
eries (64.90>. The finding by Fung and associates of 
mixed chimerism in human heart-lung allografts also 
was consistent with the Dutch observations (122). 
The fine margin between immunization and tokr-
ance was illustrated by Armstrong and colleaguc:-
who found an association between the rate of den-
dritic cell replacement and the survival of renal allo-
grafts transplanted to rats after they had been lightlY 
immunized by blood transfusions from the donor 
strain (123). Such observations and those cited 
throughout this chapter have suggested that toler-
ance induction can be efficiently and safely accom-
plished across formidable histocompatibility barriers 
without excessive alteration of the natural immuno-
logic substrate of either host or graft, explaining 
our omission of recipient pretreatment and a "non-
intervention" policy in the preparation of human in-
testinal and multivisceral allografts (124). 
With clinical solid organ transplantation, and we 
believe with bone marrow transplantation as well, the 
treatment strategy can be redefined in terms of 
achievement of two-way cell migration while using 
powerful medications or other means to avoid the 
graft destruction or GVHD that is normal and inevi-
table without such therapeutic intervention. We be-
lieve that each new immunosuppressive regimen of 
the last 30 years has allowed this phenomenon to be 
accomplished with greater consistency, but rarely to 
the extent that treatment can be stopped altogether. 
However, failure to be drug free does not mean that 
the graft acceptance is by a different process than 
originally described by Billingham, Brent, and Meda-
war who noted that "Every degree of tolerance is pos-
sible, from that which allows a homograft to live only 
a few days beyond its normal expectation ... to that 
in which it is permanently accepted and incorporated 
into its host." (15) 
The framework of understanding that these earlier 
investigators constructed (7,15) was amazingly mod-
ern and lacked only the knowledge of immunologic 
cell migration and relocation that artfully concealed 
itself from inquiring eyes for more than a third of a 
century. With appreciation of the two-way cell migra-
tion, virtually every detail of graft acceptance as it is 
induced by drugs or other methods can be reconciled 
with the original Billingham-Brent-Medawar model 
of actively acquired tolerance, accommodating in ad-
dition Woodruff's explanation of adaptation that in-
cluded as one pOSSibility replacement of certain 
elements of graft, for example connective tissue 
stroma and vascular endothelium (7,80). 
It is faScinating to realize how close Medawar him-
self came to this truth when he wrote in 1965 that" ... 
foreign kidneys do sometimes become acceptable to 
their hosts for a reason other than acquired tolerance 
in a technical sense ... One possible explantation is 
the progressive and perhaps very extensive replace-
ment of the vascular endothelium of the graft by en-
dothelium of host origin, a process that might occur 
insidiously and imperceptibly during a homograft 
reaction weakened by immunosuppressive drugs" 
(125). Woodruff's and Medawar's ideas stand today, 
modified by a fresh understanding of the nature of 
the exchanged cells, insight about where they travel, 
and the need to associated the cell migration with 
(not dissociate it from) the fundamental definition of 
tolerance. 
Although many details remain to be clarified, it 
may be said now that no matter how disparate the 
MHC compatibility or what the solid organ, the con-
sequence with effective immunosuppression is the 
rapid formation of a composite graft (chimera) within 
a short time after transplantation. The product of 
nature's workmanship is similar in the various organ 
allografts and except for greater difficulty of attain-
ment, it appears much the same in xenografts. The 
accompanying recipient changes are profound and 
contain the elusive key to understanding what toler-
ance really means at a cellular and molecular level. 
The similar nature of the donor cell migration pat-
tern after successful solid organ transplantation un-
der drug induction versus the migration pattern in 
radiation-induced xenogeneic bone marrow chimeras 
means that the "classical tolerance" defined so pre-
cisely by Billingham, Brent, and Medawar (and bone 
marrow transplanters) versus the ambiguous "graft 
acceptance" familiar to transplant surgeons are 
merely variants and stages of the same thing. In ei-
ther case, clinical success means that a characteristic 
lymphoid and dendritic cell chimerism exists that 
may be stable without further treatment, stable only 
when continued immunosuppression is provided, or 
unstable in the direction either of rejection or GVHD. 
THE CONCATENATION HYPOTHESIS 
Although cell migration is an invariable initiating 
event, it is clear that drug-free graft acceptance is not 
synonymous with permanent chimerism. However, it 
is evident that early chimerism can lead to self-
perpetuating changes in the host immune response. 
The word concatenation suggests that multiple 
linked immunologic pathways are involved in solid 
organ graft acceptance. The list has grown from an 
original suggestion in 1964 that there was a combined 
effect of clonal deletion and Woodruff's adaptation 
(51). Five years later, the list of possible mechanisms 
had burgeoned (26). "Enhancement" was added by 
borrowing a concept that originally came from stud-
ies of tumor immunology by Kaliss (127). The hy-
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pothesis was that antigraft antibodies protected the 
transplanted organ either by shielding it (peripheral 
enhancement) or by feedback inhibition of the lym-
phoid organs that secreted these antibodies (central 
enhancement). 
Another potential factor discussed in 1969 (126) 
about which little was known at the time was a defect 
in antigen processing by the macrophage system, 
caused by the circumstances of transplantation with 
immunosuppression; this concept was developed by 
Nossal (128). Apparently unaware of the concatena-
tion hypothesis, Levey subsequently presented an al-
most identical multifactorial theory stressing lithe 
delicate balance between tolerance and immunity in 
terms of antigen, antibody, and cells" (129). Since 
then, the fifth possibility of a role for special (suppres-
sor) cells that block immune reactions has been 
added (130,131). 
The concatenation hypothesis has defied both veri-
fication and repudiation, as exemplified in experi-
ments by Murase and colleagues in which ACI rat 
hearts or livers were transplanted to LEW recipients 
under short-course treatment with FK-506 (60). Re-
flecting the immunologic advantage enjoyed by the 
liver under many experimental circumstances (see 
earlier) essentially all of the hepatic grafts were ac-
cepted permanently, whereas the hearts typically 
were rejected 40 to 80 days after a 2-week course of 
FK-506 was completed. Neither kind of transplanta-
tion was associated with suppressor cell dominance 
or any other decisive single change sufficiently strik-
ing to explain why transplanted organs appeared to 
have been forgotten by the body. 
REUNIFICATION THROUGH MIXED 
CHIMERISM 
The realization that mixed chimerism is a natural 
consequence of cell migration and repopulation has 
reunited bone marrow and solid organ technology 
after an estrangement of nearly 30 years. Observa-
tions following transplantation of the intestine were 
particularly illuminating because they provided un-
mistakable microscopic evidence of chimerism with 
an organ heavily endowed with immunocompetent 
cells. Despite this, GVHD did not occur. Two analo-
gous circumstances with GVHD resistance could be 
found in seemingly unrelated research begun in the 
1970s by Slavin and Strober and their associates at 
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Stanford and in the 1980s by Ildstad and Sachs at the 
National Cancer Institute (Bethesda). 
Via Total Lymphoid Irradiation 
In Slavin and Strober's original experiments at 
Stanford, specific transplantation tolerance to skin 
and hearts was induced in adult mice and rats using 
a combination of fractionated total lymphoid irradia-
tion (TLD and donor-specific bone marrow (132,133). 
The radiotherapy regimen called TLI that had been 
developed by Kaplan for the treatment of human ma-
lignant lymphomas was known to be immunosup-
pressive but because it spared part of the central 
lymphoid organ system, it did not cause leukopenia 
or other overt myelotoxicity (134,135). Unlike the out-
come in the classic experiments that destroyed the 
host immune system with TBI, allogeneic bone mar-
row engraftment after TLI did not cause GVHD 
(17,18). Myburgh and coworkers confirmed these 
findings in baboons after kidney and liver allotrans-
plantation 036,137). 
Eventually, five clinical trials with TLI were con-
ducted-at Stanford, the University of Minnesota, 
Louvain, Belgium, Rome, and at Witwatersrand Uni-
versity in Johannesburg 038-142). All except the 
South African patients (some of whom were liver re-
cipients) underwent renal transplantation exclusively. 
The results were summarized by Myburgh at the in-
ternational congress of the Transplantation Society in 
Sydney, Australia in August 1988 (143), His report re-
vealed a striking change in therapeutic intention in 
the course of the trials. These were foreshadowed bv 
new laboratory experiments shOWing that, on the av-
erage, TLI without bOlle marrow was as effective as 
the two modalities together (142,144,145). As a conse-
quence, bone marrow was omitted altogether in the 
clinical cases from Stanford (n=2S), Belgium (n=20), 
and Rome (n=30) or used only occasionally in Min-
neapolis (5 of 22) and with decreasing frequency in 
Johannesburg (number unstipulated but known to in-
clude liver recipients). 
By the end of the multiyear clinical trial period, TLI 
had become a competitor with cyclosporine as a 
front-line immunosuppressant rather than a means to 
the end of deliberate bone marrow chimerism. Be-
cause of its inconvenience, expense, and morbidity, 
TLI lost the race. What was left when the smoke 
cleared was a group of surviving patients in each 
clinical series with thoroughly documented donor-
specific allogeneic tolerance that was explained with 
----------- - - - ------------
different versions of the concatenation hypothesis. 
Only now is it clear how chimerism (and genuine tol-
erance) can occur as the result of cell migration and 
repopulation, with or without bone marrow. 
Via Total Body Irradiation 
In investigations with TBI beginning in 1984, 
mixed syngeneic-allogeneic and syngeneic-xenoge-
neic (mouse plus rat) bone marrow chimerism was 
achieved using ex vivo syngeneic marrow instead of 
keeping intact a protected portion of the autologous 
marrow in situ as had been done in the Slavin-Strober 
models. After preparing mouse recipients with lethal 
TBI and reconstituting them with the mixed alloge-
neic (or xenogeneic) plus syngeneic marrow, stable 
multilineage mixed chimerism was present with the 
lifetime production and coexistence from both host 
and donor origin of platelets, red blood cells, T cells, 
B cells, natural killer (NK) cells, and antigen-
presenting cells (95,146-149). In individual mixed 
chimeras, the level of allogeneic chimerism varied 
widely, from 1 % to 98%. However, aUlI level of donor 
, . 
lymphoid chimerism was associated with complete 
systemic medawarian donor-specific transplantation 
tolerance. 
Just as with successful intestinal transplantation or 
in the Slavin-Strober experiments, the mixed chimeric 
state was remarkably free of the GVHD classically oc-
curring when the stem cells of the host are completely 
replaced with those of the allogeneic donor (fully al-
logeneic chimerism) (Fig. 39.3) 050-155). The doubly 
reconstituted chimeras were tolerant to skin and 
heart grafts from either contributor to the hemato-
poietic chimerism (cotolerance) (95,146-149), while 
maintaining better overall immunocompetence than 
that in the fully allogeneic chimeric state 046,151). It 
was shown recently that these mixed chimeras had 
ubiqUitous distribution of donor immunologic cells 
(especially dendritic cells) through the lymphoid and 
all other tissues of the recipient-much the same as 
after successful liver or intestinal transplantation 
(92,93,98,156). 
The recent information about mixed allogeneic and 
xenogeneic chimerism undoubtedly will stimulate 
clinical trials in which donor immunologic cells will 
be infused perioperatively at the time of solid organ 
transplantation-an iatrogenic simulation of the 
events that occur naturally during the cell migratory 
phase follOWing any kind of transplantation. The ben-
dit (and risks) will depend on factors such as donor 
cell load and timing, the quality of immunosuppres-
sion, and the degree of genetic disparity between 
donor and recipient. The infused allogeneic (or 
xenogeneic) marrow cells will have the same destina-
tion as those that leave the graft. 
The clinical exploitation of this approach should 
have potential value and minimum hazard if the con-
ventional continuous immunosuppression that has 
been developed empirically, as opposed to knockout 
therapy of the recipient immune system, provides an 
acceptable environment for the transplanted immu-
nocompetent cells without preliminary destruction of 
the recipient immunologic apparatus with suprale-
thai irradiation, drugs, and probably without the 
need for TLI. As with intestinal transplantation, ag-
gressive conditioning of the recipient to "make 
space" for the arriving donor cells may not be neces-
sary and may even be harmful. 
The use of immunocompetent donor cells to facili-
tate engraftment of solid organs will complete the 
cycle that began with the original Billingham-Brent-
Medawar spleen cell inoculation technique, which 
has taken many forms since it was first modified by 
Main and Prehn (17). The simplest version was infu-
sion of the donor white blood cell buffy coat perioper-
atively as an adjunct to kidney transplantation under 
azathioprine and prednisone. For nearly 25 years, 
Monaco has advocated that bone marrow is superior 
to all other sources of "tolerogenic" cells 057,158). In 
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a clinical trial by Barber and associates based on 
Monaco's animal protocols, donor bone marrow was 
stored and given 3 weeks after cadaver kidney trans-
plantation (159). From what has been learned of cell 
traffic, this may be too late for an optimal effect be-
cause the early events of alloreactivity would have 
been initiated. In our own human trial of induction 
of mixed allogeneic chimerism, bone marrow will be 
given at the same time as the solid organ transplanta-
tion under FK506-based immunosuppression, either 
omitting conditioning of the recipients or limiting 
this to low dose TLL 
Because solid organ transplantation already has 
reached such a high level of utility (greater than 90% 
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Fig.39.4 Long-term rejection-free survival of donor-specific 
pancreatic islet xenografts occurred in xenogeneic cizimeras. 
Chimeras were prepared and typed for chimerism at 6 weeks. 
Diabetes was induced using streptozotocin, and donor-
specific islets were placed beneatiz the renal subcapsular 
space. [II all recipients, IIormoglycemia occurred within 3 
days following placement of the donor-specific islet 
xenografts. To demonstrate that the islet xenografts were 
fllnctional to support the normoglycemic state, a transplant 
Ilephrectomy was performed at 9 months following graft 
placement. III all chimeras, the diabetic state recurred, 
demonstrating that glucose homeostasis was supported 
by the islet xenografts (153). 
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success with most kinds of grafts) without the neces-
sity for attention to histocompatibility matching or re-
cipient pretreatment, the acceptance of techniques for 
facilitation of mixed allogeneic (or even xenogeneic) 
chimerism will depend on their convenience and ex-
pense. In contrast, cell transplantation would be revo-
lutionized if the systematic production of mixed 
allogeneic chimerism proves to be feasible, no matter 
how complex and costly the recipient preparation. 
Rejection remains the major factor limiting the clini-
cal applicability of cell transplant procedures such as 
pancreatic islets (160,161). 
Apart from its use alone to treat hematologic dis-
eases and inborn errors, bone marrow as the means 
to transplant pancreatic islets or other cells is breath-
taking in its ramifications. This already has been ac-
complished in animal allograft and xenograft models 
Fig. 39.5 Anti-illsulin peroxidase stain ofa representative 
pancreatic islet xenograft 9 months after placement under 
renal sllbcapsular space in xenogeneic (rat-to-mouse) 
chimeras. Note the absence of mononuclear cell infiltrates, 
which wOllld indicate chronic rejection, alld the healthy-
appearing rcd-staining tisslle tor presence of inslliin. 
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Fig. 39.6 (Upper panels) One-way paradigm in which transplantation involves a unidirectional immune reaction: graft-
I'I!rSIIS-/lOst (GVH) with bone marrow or other lymphopoietic transplants (left) and host-verslIs-graft (HVG) with 
transplanted whole organs (right>. (Lower panels) Two-way paradigm with a bidirectional and mutually cancelling 
immllne reaction that is predominantly GVH with bone marrow grafts (left) and HVG with whole organ grafts (right). 
(Figures 39.4 and 39.5) (153). Diseases in addition to 
diabetes mellitus that are potentially treatable in-
clude muscular dystrophy (myoblasts), hepatic enzy-
matic defects (hepatocytes), hormonal deficiencies 
(adrenal medulla, adrenal cortex), coagulation de-
fects (vascular endothelial cells) and parkinsonism 
(adrenal). Many of these are the same disorders that 
would be amenable to gene therapy. It is likely that 
the two fields will merge and become complemen-
tary, allowing targeted therapy of previously untreat-
able disease states. 
SUMMARY AND CONCLUSIONS 
Historically, an allograft has been envisioned as an 
alien island in a hostile recipient sea. The corollary 
assumption was that the defenseless organ's attrac-
tiveness as a target for immunologic attack could be 
predicted by disparity between its major histocom-
patibility complex and that of the recipient. This one-
way paradigm defined transplantation immunology 
in tenns of a unidirectional immune reaction (Fig. 
39.6, top panels). We propose that the interaction of 
two coexisting donor and recipient leukocyte pop-
ulations, each to the other, is the fundamental 
explanation of both bone marrow and organ allograft 
acceptance and of transplantation tolerance generally. 
Therapeutic exploitation of the mechanisms of this 
"two-way (bidirectional) paradigm" (Fig. 39.6, bot-
tom panels) is predicted to be the basis of the next 
phase of evolution in the transplantation field, which 
will include xenotransplantation. 
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ADDENDUM 
January I, 1995-During the Festschrift at Harvard 
honoring Paul Russell's retirement in late November 
1990, Norman Shumway told one of us (T.E.S.) of his 
Thoracic Transplantation textbook for which he wanted 
one chapter on classic immunologic tolerance, and 
another on the ostensibly different mechanisms of 
whole organ allograft acceptance under chronic im-
munosuppression. On learning that we thought the 
subjects were of the same in principle, Dr. Shumway 
assigned us a chapter in which we could defend this 
opinion. 
The preparation of the manuscript was not begun 
until a year later, but then it consumed nearly 5 
months of intense and continuous effort. There had 
been no mention of a two-way immunologic reaction 
to explain organ acceptance in the voluminous litera-
ture of transplantation during the preceding four 
decades, and only a few long-ignored clues sug-
gesting that migratory leukocytes from whole organs 
persisted and were mechanistically important. Con-
sequently, the chapter was entirely hypothetical, and 
for that matter heretical, at the time it was submitted 
to the editors of Thoracic Transplantation in April 1992. 
The overwhelming evidence showing persistent 
low-level chimerism after successful transplantation 
was compiled later. This was obtained first from in-
vestigation of long-surviving liver, kidney, and other 
organ recipients 000,162-166) and then from detailed 
animal studies (167-170). The observations con-
formed perfectly with what had been predicted. Con-
sequently, the original description of the two-way 
paradigm written for Dr. Shumway has been pre-
served without any additions (except for the new 
summary and typographical corrections) or emenda-
tions. 
The now widely accepted concept that transplanta-
tion is a bidirectional immune reaction (see Fig. 39.6) 
has permitted the historic milestones in clinical trans-
plantation to be seen in a truer light (171). However, 
beacons of understanding shine forward as well as 
back. Thus, the principle of the two-way paradigm is 
being systematically applied in clinical trials of donor 
leukocyte augmentation tor whole organ recipients 
(172) and has generated research initiatives. 
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